Sign up
Pharma Capital

Pharmaxis' CEO Gary Phillips updates on partnership with Boehringer Ingelheim

Pharmaxis will receive €10 million milestone payment when the first patient is dosed in this 2nd indication Phase IIa study.

 

View full PXS profile

Pharmaxis Ltd Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.